Immunophenotypes and T-cell receptor rearrangements of AMLs with silenced CEBPA in GEP cluster no. 4
| Immunophenotypes and T-cell receptor rearrangements . | Patient no. . | |||||
|---|---|---|---|---|---|---|
| 2668 . | 2238 . | 3314 . | 2686 . | 3483 . | 3491 . | |
| T-lymphoid antigens | ||||||
| CD7 | + | + | + | + | + | + |
| SmCD3 | – | – | – | +/– | – | – |
| CyCD3 | +/– | + | – | +/– | – | – |
| CD2 | +/– | – | – | +/– | – | – |
| TdT | – | + | – | – | – | + |
| Myeloid antigens | ||||||
| CD13 | + | + partly | +/– | +/– | + | + |
| CD33 | +/– | +/– | + | +/– | +/– | + |
| CD14 | +/– | – | – | +/– | – | – |
| CD64 | – | + | – | – | – | + |
| CD11b | + | – | + | + | – | – |
| MPO | – | – | + | + | + | + |
| Stem-cell antigens | ||||||
| CD34 | + | + | + | +/– | + | + |
| CD117 | + | – | +/– | +/– | + | + |
| CD133 | – | – | – | – | +/– | +/– |
| Other antigens | ||||||
| CD45 | +/–, +/− | +/– | +/– | +/– | +/– | +/– |
| CD56 | partly | ND | + | +/– | + | ND |
| DNAs* | ||||||
| TCRD rearrangement | + | + | + | – | + | – |
| TCRG rearrangement | + | + | – | – | + | – |
| Immunophenotypes and T-cell receptor rearrangements . | Patient no. . | |||||
|---|---|---|---|---|---|---|
| 2668 . | 2238 . | 3314 . | 2686 . | 3483 . | 3491 . | |
| T-lymphoid antigens | ||||||
| CD7 | + | + | + | + | + | + |
| SmCD3 | – | – | – | +/– | – | – |
| CyCD3 | +/– | + | – | +/– | – | – |
| CD2 | +/– | – | – | +/– | – | – |
| TdT | – | + | – | – | – | + |
| Myeloid antigens | ||||||
| CD13 | + | + partly | +/– | +/– | + | + |
| CD33 | +/– | +/– | + | +/– | +/– | + |
| CD14 | +/– | – | – | +/– | – | – |
| CD64 | – | + | – | – | – | + |
| CD11b | + | – | + | + | – | – |
| MPO | – | – | + | + | + | + |
| Stem-cell antigens | ||||||
| CD34 | + | + | + | +/– | + | + |
| CD117 | + | – | +/– | +/– | + | + |
| CD133 | – | – | – | – | +/– | +/– |
| Other antigens | ||||||
| CD45 | +/–, +/− | +/– | +/– | +/– | +/– | +/– |
| CD56 | partly | ND | + | +/– | + | ND |
| DNAs* | ||||||
| TCRD rearrangement | + | + | + | – | + | – |
| TCRG rearrangement | + | + | – | – | + | – |
The following lineage markers were also analyzed, and found negative on all 6 samples: TCRα/β, TCRγ/δ, CD4, CD8, CD10, CD1a, CD65, and CD15. CD5, CD19, and CD22 were tested in 4 samples (all except for no. 2238 and no. 3491) and were negative in all these 4 cases.
+ indicates positive;–, negative; +/–, weakly positive; partly, part of population positive; and ND, not determined.
As a control, 6 GEP cluster no. 4 cases with CEBPA mutations were analyzed for T-cell receptor rearrangements as well. Patients no. 1316, no. 2242, no. 2273, no. 2545, and no. 3327 were negative for TCRD and TCRG rearrangements. Patient no. 2218 was positive for TCRG rearrangement and negative for TCRD rearrangement.